Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 1997

View Archived Issues

Inhale Therapeutic Systems: Q3 1997 highlights

Chiroscience: HY 1997 highlights

Yamanouchi: Annual Report 1997

Sequence of S. epidermidis revealed

Abbott and Biorex to collaborate on bimoclomol development

Therapeutic Antibodies and Altana enter alliance for emergency medicine products

Fujisawa launches new OTC product

COX-2 inhibitors from Chugai

Antiinfective and immunomodulatory micacocidin derivatives from Shionogi

Alpha1-antichymotrypsin analogues described in patent literature

Health Research claims peptide inhibitor of growth factors

Peptide drugs for treating leishmaniasis

BIRR-4: a new cold remedy on the horizon?

SKB claims 5-HT7 receptor antagonists

New dopamine beta-hydroxylase inhibitors derived from lettuce

AMPA receptor antagonists prepared at Schering AG

Byk Gulden describes new agents for asthma

P&G develops dihydrobenzofuran compounds for inflammation

VZV vaccines using gene product expressed during latency

Toxicity studies reported for new expectorant from SS Pharm.

Draflazine: a potential cardioprotectant with a novel mechanism of action

CS-834: a new oral carbapenem in active development at Sankyo

U-101033E vs. U-74389G in rat model of focal cerebral ischemia

Agouron to collaborate with U.K. organizations in search for anticancer drugs

Diagnon receives NCI grant for H. pylori research

New GVAX cancer vaccine begins human testing

Switch OTCs for allergies to be introduced by Fujisawa

FDA approves Follistim for IVF and ovulation induction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...